Anticoagulant efficacy of indobufen in patients with atrial fibrillation
吲哚布芬对于房颤患者抗凝疗效

摘要

非瓣膜性房颤是迄今为止中国甚至是全世界范围内广为常见的心律失常类疾病，发生率随着患者的年纪增加而逐渐升高，国内30～85岁群体中发生房颤的概率大概是0.77％，而80岁以上老年患者中发生房颤的概率则高于30％，房颤患者常因发生脑卒中而招致死亡或残疾，因此房颤患者需要长期接受抗凝治疗以降低发生死亡或残疾的风险。降低非瓣膜性房颤患者发生卒中的有效措施通常为使用口服抗凝药物，而近年来随着制药科技的不断改善和提升，吲哚布芬的问世为临床医生增加了非瓣膜性房颤患者以及PCI术后患者的抗凝用药选择，临床医生可以根据自身的临床经验并结合患者的病情需求，为患者制定出合适的抗凝药物的使用方案，本文对吲哚布芬的抗凝机制和其对非瓣膜性房颤患者的临床疗效方面进行阐述。

Abstract

Non-valvular atrial fibrillation is a common arrhythmia disease in China and even in the world so far. The incidence rate gradually increases with the age of the patients. Atrial fibrillation occurs in the 30-85-year-old group in China. The probability of atrial fibrillation is about 0.77%, and the probability of atrial fibrillation in elderly patients over 80 years old is higher than 30%. Patients with atrial fibrillation often lead to death or disability due to stroke, so patients with atrial fibrillation need long-term anticoagulation. Treatment to reduce the risk of death or disability. The effective measures to reduce the occurrence of stroke in patients with non-valvular atrial fibrillation are usually the use of oral anticoagulants. In recent years, with the continuous improvement and improvement of pharmaceutical technology, the advent of indobufen has increased the number of non-valvular atrial fibrillation patients for clinicians. As well as the choice of anticoagulant drugs for patients after PCI, clinicians can formulate appropriate anticoagulant drug use plans for patients based on their own clinical experience and the needs of patients. It describes the clinical efficacy of patients with non-valvular atrial fibrillation.